An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Among these was a product called VIP Go Rhino Gold 69K from a sex shop in Quebec City, Quebec; Alien 2 Power Platinum 11000 ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...

Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ensure supply.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...